108281-79-4

Basic information

• Product Name: 6-BROMO-1,2,4-TRIAZOLO[4,3-1]PYRIDINE
• Synonyms: 6-BROMO-TRIAZOLO[4,3-A]PYRIDINE;6-Bromo[1,2,4]triazolo[4,...;6-BROMO-1,2,4-TRIAZOLO[4,3-1]PYRIDINE;6-BROMO-[1,2,4]TRIAZOLO[4,3-A]PYRIDINE;6-Bromo-[1,2,4]triazolo[4,3-a]pyridine 98%
• CAS NO: 108281-79-4
• Molecular Formula: C₆H₄BrN₃
• Molecular Weight: 198.02006
• EINECS: 251-156-6
• Product Categories: blocks;Pyridines;Heterocycle-Pyridine series
• Mol File: 108281-79-4.mol
• Article Data: 6

Chemical Properties

• Melting Point: 151-153
• Appearance: /
• Density: 1.891 g/cm³
• Refractive Index: 1.751
• Storage Temp.: Keep Cold
• PKA: 2.38±0.50(Predicted)
• CAS DataBase Reference: 6-BROMO-1,2,4-TRIAZOLO[4,3-1]PYRIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BROMO-1,2,4-TRIAZOLO[4,3-1]PYRIDINE(108281-79-4)
• EPA Substance Registry System: 6-BROMO-1,2,4-TRIAZOLO[4,3-1]PYRIDINE(108281-79-4)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22
• WGK Germany: 3
• Hazardous Substances Data: 108281-79-4(Hazardous Substances Data)

Usage

General Description

6-Bromo-1,2,4-triazolo[4,3-a]pyridine, also known as BTP, is a chemical compound with a molecular formula C5H3BrN4. It is a heterocyclic organic compound that contains a pyridine ring fused to a triazole. BTP is used as a building block in the synthesis of pharmaceuticals and agrochemicals, particularly in the development of new drugs and crop protection products. It is known to exhibit biological activity and has been studied for its potential as an anti-inflammatory and anti-cancer agent. BTP is a highly versatile compound with a range of potential applications in the fields of medicine, agriculture, and materials science.

InChI:InChI=1/C6H4BrN3/c7-5-1-2-6-9-8-4-10(6)3-5/h1-4H

Upstream product

• 14036-06-7 diethoxymethyl acetate 
• 77992-44-0 5-bromo-2-hydrazinylpyridine 
• 77992-44-0 5-bromo-2-hydrazineylidene-1,2-dihydropyridine 
• 122-51-0 orthoformic acid triethyl ester 
• 53939-30-3 5-bromo-2-chloropyridine 
• 68-12-2 N,N-dimethyl-formamide 
• 50-00-0 formaldehyd 
• 624-28-2 2,5-dibromopyridine 

Downstream Products

• 1313488-94-6 N-(5-([1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-chloropyridin-3-yl)-4-fluorobenzenesulfonamide 
• 1426845-59-1 5-([1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1426845-60-4 5-(3-bromo-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-(4-fluorophenyl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1426845-31-9 2-(4-fluorophenyl)-5-(3-(4-fluorophenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-N-methyl-6-(N-methylmethylsulfonamido)benzofuran-3-carboxamide 
• 1609565-58-3 N-(5-(3-bromo-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1609565-56-1 2,4-difluoro-N-(5-(3-(3-hydroxyprop-1-yn-1-yl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1609565-57-2 N-(5-([1,2,4]triazolo[4,3-a]pyridin-6-yl)-2-methoxypyridin-3-yl)-2,4-difluorobenzenesulfonamide 
• 1609565-59-4 2,4-difluoro-N-(5-(3-(3-hydroxybut-1-yn-1-yl)-[1,2,4]-triazolo[4,3-a]pyridin-6-yl)-2-methoxypyridin-3-yl)benzenesulfonamide 
• 1262618-40-5 6-(4-(trifluoromethoxy)phenyl)-[1,2,4]triazolo[4,3-a]pyridine 
• 1084810-52-5 8-([1,2,4]triazolo[4,3-a]pyridin-6-yl)-5-(3,5-difluorophenoxy)-2-methyl-2,3,4,5-tetrahydro-1H-benzo[c]azepine 

Relevant articles and documents

Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73

CD73 is an extracellular mediator of purinergic signaling. When upregulated in the tumor microenvironment, CD73 has been implicated in the inhibition of immune function through overproduction of adenosine. Traditional efforts to inhibit CD73 have involved antibody therapy or the development of small molecules, the most potent of which mimic the acidic and ionizable structure of the enzyme's natural substrate, adenosine 5′-monophosphate (AMP). Here, we report the systematic discovery of a novel class of non-nucleotide CD73 inhibitors that are more potent than all other nonphosphonate inhibitor classes reported to date. These efforts have culminated in the discovery of 4-({5-[4-fluoro-1-(2H-indazol-6-yl)-1H-1,2,3-benzotriazol-6-yl]-1H-pyrazol-1-yl}methyl)benzonitrile (73, IC50 = 12 nM) and 4-({5-[4-chloro-1-(2H-indazol-6-yl)-1H-1,2,3-benzotriazol-6-yl]-1H-pyrazol-1-yl}methyl)benzonitrile (74, IC50 = 19 nM). Cocrystallization of 74 with human CD73 demonstrates a competitive binding mode. These compounds show promise for the improvement of drug-like character via the attenuation of the acidity and low membrane permeability inherent to known nucleoside inhibitors of CD73.

FUSED RING DERIVATIVE AS A2A RECEPTOR INHIBITOR

Disclosed are a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an application of the compound or slat in preparation of drugs for treating diseases related to an A2A receptor.

HETEROAROMATIC COMPOUNDS AS PI3 KINASE MODULATORS AND METHODS OF USE

The present invention provides heteroaromatic derivatives and pharmaceutical acceptable salts and formulations thereof useful in modulating the protein kinase activity, especially phosphatidylinositol 3-kinases (PI3 kinases) and mTOR, and in modulating inter- and/or intra-cellular signaling activities such as proliferation, differentiation, apoptosis, migration and invasion. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.